



University
of Basel

Faculty of
Medicine



ECPM – European Center of Pharmaceutical Medicine

Institute of Pharmaceutical Medicine

Annual Report 2023.

ECPM[®] 
European Center of Pharmaceutical Medicine

CONTINUING
EDUCATION

Table of Contents

Foreword.	3
Introduction	3
The ECPM at a glance.	4
ECPM Course Offer	4
ECPM Research Activities	5
Facts & Figures – ECPM in 2023	5
Organizational chart.	6
European Center of Pharmaceutical Medicine.	7
Institute of Pharmaceutical Medicine.	7
Director	7
Education & Training.	8
Personnel.	8
Head of Education & Training, Managing Director	8
Course Director	9
Course Coordinator	9
Research.	11
Personnel.	11
Head of Research	11
Senior Research Scientist	12
PhD Candidate	15
Co-Supervision of PhD/MMD projects.	15
PhD/MMD Candidates.	15
Education & Training.	16
Current Status.	16
Undergraduate / Graduate Teaching	16
Postgraduate Training	16
The following postgraduate courses were offered in 2023:	17
Education & Training.	18
Objectives for the coming years.	18
Education & Training.	19
ECPM Training Opportunities	19
ECPM Certificate and Diploma Course (CAS, DAS) in Pharmaceutical Medicine	19
Master Course (MAS) in Medicines Development	19
Frontiers in Drug Development Seminars	20
Examination	20
Multiple choice examination (MCQ):	20
Oral/Essay examination:	20
E-learning	20
Electronic Learning Platform	21
Education & Training Projects in 2023	21
Planned Education & Training Projects for 2024	21
Expertise for Approval of Radioactive Diagnostics and Therapeutics	22
PharmaTrain Syllabus working party	22
Undergraduate Teaching at the University of Basel Medical School	22
Undergraduate Teaching at the University of Basel, Faculty of Science	22
Undergraduate Teaching at the University of Zurich	22
Undergraduate Teaching at the University of Bern	23
Postgraduate Teaching at the University of Basel	23
Postgraduate Teaching at the University of Zurich	23
Postgraduate Teaching at the University of Lausanne	23
Research.	24
Current Status.	24
Key Areas of Expertise	24
Research.	25
Objectives for the coming years.	25
Research.	26
Overview of activities.	26
Basel University Hospitals	27
University of Basel and Swiss Tropical and Public Health Institute (Swiss TPH)	27
National and international academic units and collaborative study groups	27
Public entities	28
Private entities	28
Research.	29
Upcoming Projects: outlook 2024.	29
Research.	30
New Projects (started in 2023).	30
Research.	32
Ongoing projects.	32
Research.	36
Completed projects.	36
Activities of the ECPM collaborators in 2022.	36
Publications, Scientific Presentations, Evaluation of Research Projects and Thesis Supervision.	38
Scientific Presentations to External Audiences	42
Evaluation of Research Projects and Publications (peer review)	43
PhD Theses Supervised by the ECPM Collaborators in 2023	44
Master Theses: MBA, MMD and MPH	44

Foreword.

Leading with Excellence in Pharmaceutical Education and Research

Introduction

The field of medicines development is undergoing a period of unprecedented transformation. In this dynamic environment, postgraduate education plays a critical role in ensuring that pharmaceutical industry professionals possess the most up-to-date knowledge and skills. This report explores the vital contributions of the European Center for Pharmaceutical Medicine (ECPM) in Switzerland and its international partners. We will delve into the importance of postgraduate education, examine the structure and historical context of ECPM's course offerings, and highlight the value of comprehensive training across all facets of medicines development. From discovery and clinical trials to regulatory affairs and marketing, ECPM equips professionals with the expertise needed to navigate this complex and ever-evolving landscape. Furthermore, by fostering collaboration between key stakeholders in the healthcare system, ECPM has played a pivotal role in standardizing and elevating the quality of education in this crucial field. Anchored by the PharmaTrain syllabus, ECPM's courses not only provide essential skills but also ensure that professionals remain at the forefront of emerging trends and technologies.

The research activities of ECPM, embedded in the Department of Public Health (DPH) of the Medical Faculty, focus on health technology assessment, health economic evaluation and health services research. Over the past 19 years, the ECPM research group has maintained its position as one of the most active health economic groups in Switzerland, in terms of publication activity, project scope, and scale. Recent key developments were the establishment of the Health Economics Facility (HEF) at the level of the DPH, essentially grounded in ECPM's history of related expertise, and the foundation of the interfaculty Basel Center for Health Economics (BCHE), where we join forces with the Health Economics Professorship at the Faculty of Business & Economics and the Household Economics & Health Systems Research Unit at the Swiss TPH. The BCHE opens windows to the outside world, engages with society, facilitates collaborations and the acquisition of large scale projects, and allows to plan for an upscaling of health economics education at our University. The HEF systematically provides and develops cooperation opportunities for clinical researchers at the Basel University Hospitals, e.g. in the context of investigator-initiated clinical trials funded by the Swiss National science Foundation, and other interested parties.



Prof. Thomas D. Szucs
Director



Dr. Annette Mollet
Head of Education & Training



Prof. Matthias Schwenkglens
Head of Research

The ECPM at a glance.



Number of students

(1991–2023)

2232



Nationalities of students

(2021–2023)

25



Faculty Members

(overall)

150

ECPM Course Offer

Our mission at ECPM is to establish the best international training platform that provides and enhances the knowledge, expertise and skills required to perform modern discovery, development, regulation and marketing of medical products.

Since our foundation in 1991, we have trained over 2,100 students holding MDs, PhDs or an MSc, and recruited 150 members of faculty. Furthermore, since the introduction of the Bologna system in 2000, ECPM was proud to upgrade from awarding a certificate to the possibility of awarding a postgraduate diploma. From 2009 to 2014, Fritz R. Bühler, Thomas D. Szucs, Susanne Daniel and Annette Mollet led the Innovative Medicines

Initiative (IMI) project – a public/private partnership called PharmaTrain. Through this European academic network the ECPM training platform was taken to the next level to offer a postgraduate Master title. In 2006 and 2008, the University of Beijing and the subsidiary of the University of San Francisco in Washington adopted the course concept.

With excitement ECPM has continued to expand its global footprint by celebrating the graduation of its participants from the inaugural Executive Training Program on Drug Development and Regulatory Science in 2023 with the Prasanna School of Public Health in India and in partnership with the Roche Healthcare Institute in India.

Educational background of students


(2023 – 2025)



PhD Pharmacy	5.6%
PhD Engineering	1.9%
PhD Chemistry	5.6%
PhD Biotechnology	15.7%
MD PhD	15.7%
MD	25.9%
MBA	2.8%
MSc Pharmacy	6.5%
MSc Life Science	5.6%
MSc Veterinary	0.9%
MSc Communication	1.9%
MA Economics	0.9%
MA Law	0.9%
MD MSc	5.6%
PharmD	0.9%
BSc Chemistry	1.9%
BSc Biology	1.9%
Total	100.0%

Workplace of students

(2023 – 2025)



Small to Medium Size Pharma	13%
Big Pharma Top 20	55%
CROs, Expert Services	5%
Regulatory Authority	9%
University Hospitals	8%
Academia	2%
Medical Supplies	1%
Freelance	3%
Medical Practice	2%
Consulting	3%
Total	100%

Teaching Faculty

(2023 – 2025)



Big Pharma	31%
Small and Medium Sized Enterprises	9%
CRO	7%
Regulatory Authorities	20%
Academia/ University Hospitals	23%
Consultants	9%
Total	100%

ECPM Research Activities


The Research department started its activity in 2003 with a focus on health economic characteristics, cost-benefit implications and efficient use of pharmaceuticals and other healthcare interventions in Switzerland and internationally.

We maintained our position as one of the most active health technology assessment, health economics and health services research groups in Switzerland, with a high level of publication activity and co-operations with multiple partners.

Facts & Figures – ECPM in 2023

- Director Thomas D. Szucs was bestowed the title of Honorary Professor from Peking University
- Established a new partnership with Bristol Myers Squibb
- Expanded its international reach by completing an inaugural course cycle with a new partner university in India: The Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India
- ECPM course India was nominated for the TOPRA 2023 Awards in 'Regulatory Excellence'
- Had the final CAS/DAS examinations for the 16th ECPM diploma course cycle
- Awarded 21 CAS and 54 DAS to our 2021-23 participants
- Started the 17th ECPM diploma course cycle with 108 new participants (overall >2,100)
- Collaborated with 150 faculty members from different affiliations
- Developed and offered special modules and lecture series
- Was involved in graduate and postgraduate teaching of 10 different programs
- Held the inauguration of the Basel Center of Health Economics (BCHE) and continued to develop the Health Economics Facility at the Department of Public Health (with Matthias Schwenkglenks as founding member/lead)
- Acquired about 880,000 Swiss Francs in third-party research funding
- Embarked on a new European Union HORIZON Europe project (EPIC - Enhancing Palliative Care in Intensive Care) as a consortium partner
- Won the accompanying research alongside the new integrated care model Réseau de l'Arc, established in the Jura region, in cooperation with BCHE and Swiss TPH colleagues
- Continued developing research expertise in health economic evaluations, budget impact analysis, health technology assessment, health services and outcomes, insurance claims data, systematic reviews and meta-analysis, applied behavioral economics, epidemiology, and biostatistics
- Trained undergraduate and graduate students from medicine, pharmacy, human biology, public health and nursing
- Supervised 3 PhD students in Basel and 2 in Zurich
- Authored and co-authored 25 published peer-reviewed articles and multiple conference abstracts
- Gave multiple scientific presentations to external audiences
- Welcoming new education and research staff

Organizational chart.



European Center of Pharmaceutical Medicine. Institute of Pharmaceutical Medicine.



Director

Thomas D. Szucs, MD MBA MPH LL.M JSD is Professor of Pharmaceutical Medicine and Director of The Institute of Pharmaceutical Medicine/European Center of Pharmaceutical Medicine at the University of Basel.

He is also a Professor and part-time lecturer for Medical Economics at the University of Zurich and an honorary professor at the University of Peking Health Science Center. Previously he was Chief Medical Officer of Hirslanden Holding, the largest private hospital chain in Switzerland.

From 1998 to 2001, he was head of the Department of Medical Economics, a joint venture of the University Hospital in Zurich and the Institute of Social and Preventive Medicine of the University of Zurich. Professor Szucs' former appointments include head of research and founder of the Center of Pharmacoeconomics of the University of Milan, head of the working group for Clinical Economics at the University of Munich, senior consultant at Arthur D. Little Inc. and head of the Department of Health Economics at F. Hoffmann-La Roche Ltd. in Basel.

He holds a medical degree from the University of Basel, a Master in Business Administration from the University of St Gallen, Switzerland, a Master of Public Health degree from Harvard University, a LL.M in International Business Law from the University of Zurich and a Doctorate in Law from the Private University of Liechtenstein. Thomas is board certified in Pharmaceutical Medicine as well as in Prevention and Public Health.

He is also member of the editorial board of several scientific journals. So far, he has published more than 400 articles, book chapters and monographs. He has worked extensively in the field of pharmaceutical economics and epidemiology. From 2004–2014 he was the president of the Swiss Association of Health Economics. In 2010, he was appointed Chairman of Helsana Insurance, Ltd, the largest health insurer in Switzerland. Since then, Thomas Szucs has been in charge of the overall supervision of the Executive Board. In 2016, Professor Szucs was rated among the 20 most influential economists in Switzerland. In 2020, he was recognized as a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. Since 2013, he started to work as a clinician in genomic medicine. In 2020, he was appointed as Co-Director Genomic Medicine at the Hirslanden Private Hospital Group, which consists of 17 hospitals.

Education & Training. Personnel.

The European Center of Pharmaceutical Medicine (ECPM), founded in 1991, has established a reputation as one of the premier European training centers in Pharmaceutical Medicine. The ECPM training platform offers undergraduate/graduate training for medical and life sciences students and postgraduate training on three different levels in the field of Pharmaceutical Medicine/Drug Development Sciences.

The first postgraduate level represents the ECPM Certificate/Diploma of Advanced Studies course, (CAS 20 ECTS / DAS 30 ECTS), which can then be complemented on a second level with Continuing

Professional Development (CPD) short courses. The third level involves a thesis to achieve the Master of Advanced Studies in Medicines Development (MAS, 60 ECTS).

We collaborate locally with the Department of Clinical Research at the University Hospital in Basel and University of Zurich, as well as Europe wide with universities in the PharmaTrain network, such as the Kings College London, United Kingdom, and internationally with the Peking University Clinical Research Institute at the University of Beijing, University of San Francisco and Manipal Academy of Higher Education in India.



Head of Education & Training, Managing Director

Annette Mollet, PhD, dipl. Pharm. Med. SwAPP, MBA is Managing Director and Head of Education & Training of the ECPM at the University of Basel since 1997.

Annette holds a Master in Pharmacy from the University of Basel and a PhD in Neurobiology from the Swiss Federal Institute of Technology in Zurich and an MBA in International Health from the Swiss Tropical and Public Health Institute (Swiss TPH). She teaches drug development both at the Universities of Basel and Zurich. In 1997 Annette joined the clinical R&D department at F. Hoffmann-La Roche in Basel. She was responsible for the conduct of Phase II and Phase III trials and later worked as a Medical and Product Manager for oncology products at Roche Pharma Schweiz.

She is chairing the Federal Expert Committee for the Evaluation of Radioactive Drugs, a joint committee of the Swiss Agency for Therapeutic Products (Swissmedic) and the Swiss Federal Office of Public Health (BAG) since 2007, being a member since 1994. She was a founding member and Member of the Board of the Swiss Association of Pharmaceutical Professionals (SwAPP) and was active in SwAPP's commission for specialty training and Continuing Professional Education (CPD) from 1999 until 2018.

She was also involved as a Program Manager in the creation of a European specialist title in Pharmaceutical Medicine and of a Master title in Medicines Development within the Innovative Medicines Initiative (IMI) from 2009 until 2014. She chairs the PharmaTrain Federation (successor project after termination of the PharmaTrain project in 2014) working group of course providers in Pharmaceutical Medicine.

From 2016 –2021, Annette was member of Board of the Association of Graduate Regulatory Educators (AGRE global) based in the USA. She is the co-author of the Dictionary of Pharmaceutical Medicine by Springer (fourth edition, 2017) and was a member of the working party on the “PharmaTrain Syllabus for Pharmaceutical Medicine” lead by the Royal College of Physicians in London. Since April 2017, Annette forms part of the Committee of Continuing Education of the University of Basel. From 2018 until 2022, she was elected External Examiner at the Trinity College of the University of Dublin for the curriculum in Pharmaceutical Medicine.

In 2020, she was recognized as Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. From

2021 until 2023, Annette was elected Board Member of IFAPP(International Federation of Association of Pharmaceutical Physicians and Pharmaceutical Medicine) where she chaired the “Young Professionals” working group. Its objec-

tive is to raise awareness in young people at the beginning of their career of the discipline, training possibilities and job offerings in the field of Pharmaceutical Medicine.



Course Director

Nastazja Monika Laskowski has been Course Director at ECPM since May 2023. She received her BSc in Neuroscience in 2017 from University College London and her MSc in Genomic Medicine in 2019 from Cambridge University, United Kingdom. In 2020, Nastazja began her PhD thesis in collaboration with Roche Pharmaceuticals where she is carrying out research in artificial intelligence and data sharing. She graduated from the

diploma course at ECPM in 2021 and also holds a professional qualification in genetic counselling. Her clinical training for genetic counselling was completed in Oxford University Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust and Great Ormond Street Hospital Trust in the United Kingdom. She was involved in evaluating the role out of Whole Genome Sequencing into the English National Health Service.



Course Coordinator

Nicola Liversidge is responsible for the course coordination at the European Center of Pharmaceutical Medicine since 2023. She earned a BA in Psychology at Webster University Geneva and a Master's in International Business from Hult University in Shanghai. Previously she

worked as a recruiter for CTC Resourcing Solutions, served as Deputy Operative Lead for the Triage and Test Center at the University Hospital of Basel, and has held various positions at Syngenta.



The Biozentrum of the University of Basel is the training venue for the ECPM post-graduate course program.
Picture: © Atelier Fontana, Basel)

Research. Personnel.

The ECPM's research activities focus on the health economic characteristics, cost-benefit implications and efficient use (e.g. guided by predictive testing or risk stratification models) of pharmaceuticals and other healthcare interventions in Switzerland and internationally. They have a close relationship with modern Health Technology Assessment and imply the use and integration of health economic and pharmacoeconomic evaluation methodology (cost effectiveness, cost utility, application of advanced modeling techniques), outcomes and clinical research (i.e., randomized clinical trial and observational study) methodology, and biostatistics. Complementary activities occur in related fields such as health systems research, health services research including work with large real-world datasets, clinical epidemiology and pharmacoepidemiology.

Health economic evaluation studies, which are a mainstay of ECPM's research activities, integrate clinical evidence with medical resource use and cost data to analyze the value for money provided by new or long-used drugs and other health care interventions. The overarching question is how scarce health care resources can be optimally used to maximize patient benefit and support the sustainability of healthcare systems. The results of this type of research are an important prerequisite of informed and transparent health policy decision making.

Clinical fields addressed by ECPM studies include, amongst others, oncology and hematology, cardio-vascular disease and heart failure, geriatrics, palliative care, neurology, ophthalmology, infectious diseases, and vaccinations.



Head of Research

Matthias Schwenkglens, PhD, MPH has been ECPM's Head of Research since 2003. In 2022, Matthias was appointed as Head of the Health Economics Faculty (HEF), which has been endorsed in 2022 as an integrated part of the Faculty of Medicine's research infrastructure. He also is a founding member and co-director of the interfaculty Basel Center for Health Economics (bche) established in 2023.

In 2021, he was appointed Research Group Leader at the Department of Public Health of the Medical Faculty. Since 2010, he also leads the Medical Economics Unit at the Epidemiology, Biostatistics and Prevention Institute of the University of Zurich. Among other commitments, he acts as a health economics expert for the Cancer Screening Committee set up within the framework of the Swiss National Strategy against Cancer, and as an advisor for the Swiss Healthcare Atlas project led by the OBSAN. Matthias obtained a Master of Arts in Sociology and Political Sciences from the University of Tübingen, a Master of Public Health from the

Universities of Basel, Bern and Zurich, and a PhD in Epidemiology from the University of Basel. In 2009, he received the Venia Legendi in Health Economics and Public Health from the Medical Faculty of the University of Zurich, and was subsequently appointed Professor (Titularprofessor) in 2016.

He previously headed the Department of Medical Economics at the Hirslanden Private Hospital Group, Zurich, and worked as a Research Fellow at the Department of Medical Economics of the University of Zurich. He also has extensive professional experience in internal intensive care nursing.

His current research interests and teaching activities are in the fields of health economics, health economic evaluation and modeling, Health Technology Assessment, health services research with large real-world datasets, epidemiology, observational study and trial design, and biostatistics.



Senior Research Scientist

Michaela Barbier, PhD is a Senior Research Scientist and lecturer at ECPM since 2018.

She holds a Master in Mathematics and Economics (“Wirtschaftsmathematik”) and a PhD in Biostatistics, both from the University of Ulm. Alongside her PhD, she already worked on industry-funded projects in biostatistics but was also involved in teaching activities.

She is an experienced biostatistician with more than 13 years’ expertise in healthcare across academia, the pharmaceutical industry and consulting, with her work spanning health economics and outcomes research, Health Technology Assessments, biostatistics and real world evidence.

Michaela has a vast experience of drug development and clinical trials after working for many years as a (senior) statistician at Novartis. As a later consultant, she expanded her knowledge in health economics with projects ranging from Health Technology Assessments, health economic evaluations and modeling, real world database analyses and also market access. She acquired knowledge of a wide range of indications including among others oncology, cardiovascular, respiratory and ophthalmology.

Her current research interests remain in health economic decision modeling, biostatistical modeling, health service research and value-based health care.



Senior Research Scientist

Judith Lupatsch, PhD is a Senior Research Scientist and lecturer at ECPM since 2017.

She has a degree in social sciences from the University of Mannheim, where she focused on judgment and decision models as well as behavioral psychology. After working in several projects, she continued with a master’s degree in economics at the University of Bern, where she became interested in econometrics and health economics. Her thesis was on developing and modeling preference-based utility measures for health economic evaluations. She undertook a PhD in epidemiology and biostatistics at the Institute of Social and Preventive

Medicine (ISPM) in Bern where she had the chance to deepen her modeling and data analysis skills, especially in cancer epidemiology. After the PhD she continued with a post-doctoral fellowship at the institute national de la santé et de la recherche médicale (INSERM) in Paris, France. At the ECPM, she is mainly responsible for health economic and health service research projects in cooperation with the Swiss Group for Clinical Cancer Research (SAKK).

Her current research interests focus on health economics, HTA, epidemiology and health service research, especially modelling aspects.



Senior Research Scientist

Nadine Schur, PhD is a Senior Research Scientist at the ECPM since 2015.

She studied Biomathematics at the University of Applied Science Zittau / Goerlitz, Germany, before obtaining a Master of Science in Epidemiology at the University of Basel in 2008. Afterwards, she worked on her PhD thesis “Geostatistical modeling of schistosomiasis transmission in Africa” at the Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute (Swiss TPH), Basel that she published in 2011.

She continued her work at the Swiss TPH on the spatial distribution of neglected tropical diseases in Africa for another year where she was also involved in teaching.

Then, she started a new position as Research Associate at the Department of Infectious Disease Epidemiology, Imperial College London, analyzing demographic and behavior-related factors as well as temporal trends associated with the HIV epidemic in Zimbabwe. She also gained knowledge on the conception and implementation of epidemiological studies in the framework of the Manicaland Project. During her years of research, she has had the opportunity to develop various techniques in health research methodology from systematic reviews to disease modeling.

Her current research interests are in the areas of epidemiology, health economic evaluations and biostatistics focused on multi-variable regression analysis, epidemiological and decision-analytic modeling, and real-world database analyses.



Senior Research Scientist

Sandro Stoffel, PhD is a Senior Research Scientist at ECPM since 2019

He holds a Master in Business Administration from the University of Fribourg, a Master in Development Economics from the University of Rome Tor Vergata and a Master in Economic Theory from Paris-Sorbonne University. After completion of his PhD in Economic Theory at the University of Rome Tor Vergata, he worked as a Behavioural Researcher at the Joint Research

Centre of the European Commission on projects applying insights from behavioral economics to preventive health behaviors. He then moved to UCL and later to the University of Aberdeen, before joining ECPM.

His current research interests are in behavioral health economics, medical decision making and survey methodology



Senior Research Scientist

Mark J. Lambiris has been a senior health economist at ECPM and the Health Economics Facility since 2023.

He previously was a senior health economist at the Swiss Tropical and Public Health Institute. Prior to that he worked as an economist, with big datasets in the areas of health and labour markets and held positions at the University of Lausanne, the Lausanne University Hospital, the Internal Displacement Monitoring Centre in Geneva, the Hellenic Army and in the financial services sector in London.

His has worked extensively on health economic evaluations (cost-effectiveness analyses of drugs or interventions), HTA, the application of causal inference methods to real-world data (health insurance claims, electronic medical records, social security datasets), implementation

research, and evidence synthesis (meta-analysis). His work has spanned multiple disease and health areas, including infectious diseases, antimicrobial resistance, child and cognitive development, mental health, cancer and multiple sclerosis. During his time at ECPM he taught health economics as part of a course aimed at nursing science students and introduction to causal inference to medical students. He also taught statistics and econometrics to Bachelor of Economics students at the University of Lausanne from 2012 to 2017.

He holds a PhD in Economics from the University of Lausanne, a Masters in Economics from the London School of Economics and a Bachelor in Psychology from the University of Surrey.



Senior Research Scientist

Dante Salvador, MD, MPH, PhD is a Research Scientist at ECPM since 2023.

He holds BSc in Biology, Doctor of Medicine, Master in Public Management and initially worked as a health systems manager and rural physician in a remote and resource-limited municipality in central Philippines from 2012 to 2014. The experience inspired him to work and focus in health economics and policy. He completed a dual Masters in Public Health (European Public Health) from University of Sheffield, United Kingdom and Jagiellonian University, Poland through an Erasmus+ scholarship from 2015 to 2017. Since then he has completed several national government projects related to control and prevention of ill-effects of tobacco and alcohol through taxation. He also completed projects for the national health insurance agency in the Philippines from 2018 to 2020.

He moved back to Europe when he was granted a Marie Skłodowska-Curie Actions (MSCA) doctoral training fellowship, and pursued his PhD in Health Sciences (Epidemiology and Biostatistics) at University of Bern wherein he focused on finding associations between diabetes and cardiovascular outcomes, particularly on potential clinical targets measured using cardiovascular MR and carotid ultrasound that are not currently being used as part of clinical guidelines.

After PhD, he started at ECPM to reignite his passion for health economics and health technology assessment, wherein he currently leads several health economic evaluation of clinical trials and public health interventions. Apart from these, he is also interested in improving transparency and communication of health economic studies through reproducible analysis and standardized reporting.

Co-Supervision of PhD/MMD projects.

PhD/MMD Candidates.



PhD Candidate

Niklaus Meier, MSc, BSc, studied economics and applied economic analysis at the University of Bern with a specialization in applied empirical methods in the fields of health and public policy. Through his subsequent work as a research associate for health economics at the Bern University of Applied Sciences, he became familiar with health technology assessment and cost-effectiveness analysis. This experience enabled him to start his PhD at ECPM, under the principal supervision of Matthias Schwenkglens, in 2021. His PhD focuses on cost-effectiveness analyses of medical interventions for haemophilia with a particular emphasis on treating haemophilia via gene therapies. For this, he

is developing a microsimulation model to compare potential gene therapies with the current standard of care. Niklaus further plans to conduct a systematic literature review for cost-effectiveness analyses of haemophilia interventions with a focus on reviewing the clinical effectiveness evidence that was used to inform the models. For his final project, he plans to draw on the insights from the previous research to develop or refine methods for cost-effectiveness analyses and specific techniques for quantifying uncertainty and the expected value of information.



Professor Thomas D. Szucs, Director of ECPM, delivering a lecture for the ECPM Course participants.

Education & Training.

Current Status.

The European Center of Pharmaceutical Medicine (ECPM) has established a reputation as one of the premier European training centers in Pharmaceutical Medicine. Training is offered at undergraduate, graduate and postgraduate levels. On a postgraduate and Continuing Professional Development (CPD) level, courses provide expert knowledge in drug development, pharmaceutical medicine, clinical research, and regulatory sciences.

The ECPM Diploma Course represents the core of the postgraduate training platform. It covers the training need of specialists working in one or the other phase in drug development and provides a holistic view of the process and comprehensive instructions for integrating cutting-edge concepts and best practices in medical product development and regulatory sciences.

The focus of the ECPM training platform is to teach integrated medicines development with emphasis on requirements for rational and rapid development of a new product for the global market. The course programs cover all aspects of pharmaceutical medicine and drug development and regulatory sciences as defined by the IMI PharmaTrain syllabus.

Undergraduate / Graduate Teaching

The ECPM employees teach a variety of graduate-targeted courses in pharmaceutical medicine, health economics and health policy. Courses are offered within the Medical Faculty / Department of Public Health and the Pharmacenter of the University of Basel, as well as at the Medical Faculty and Science Faculty of the University of Zurich. Lectures are held in English and German. For details, please refer to the listing of teaching and training activities

Postgraduate Training

The largest training offer remains the ECPM Diploma Course with approximately 100 participants running over two years. The current course cycle started in September 2023 and will be finished in August 2025. The course has been offered successfully for 32 years. The Diploma of Advanced Studies in Pharmaceutical Medicine can be extended with Continuing Professional Education (CPD) short courses and a Master Thesis to achieve a Master of Advanced Studies in Medicines Development. So far 12 candidates have obtained the Master's degree.

In 2012, 2018 and 2024 ECPM received the "Centre of Excellence" accreditation by the Innovative Medicines Initiative (IMI) PharmaTrain. This certifies that ECPM adheres to the IMI Education & Training Quality Standards as well as to the PharmaTrain Syllabus, Learning Outcomes and Curriculum for Training in Pharmaceutical Medicine.

The following postgraduate courses were offered in 2023:

Diploma Course (DAS) in Pharmaceutical Medicine

The 17th cycle started in September 2023 and ends with the examination in August 2025.

Fundamentals in Health Economics

This course addresses the role of health-economic thinking in the drug development process. Participants are provided with an understanding of the key principles and methodological concepts of health economics. This course enables them to assess and appraise published health economic analyses according to guidelines

Scientific Medical Writing

This course provides a comprehensive overview of the strategic scientific and medical writing field and offers hands-on training in writing and analyzing scientific texts. In particular, it conveys key elements principles for proficient scientific writing.

Project Management in the Life Sciences Industry

This intensive 6-day course (in two parts) focuses on projects in the life sciences industry and the

clinical trial setting ranging from pre-clinical to phase III studies and post-marketing studies. It teaches all the relevant steps and techniques to accurately plan, conduct, and evaluate life sciences projects.

Participants benefit from instructor-led training and group work on real case studies. They work on projects characterized by a high degree of complexity requiring professional management at all stages and levels.

Study Trip to Estonia

The aim of the study trip was to study the health care system and to get an overview of the electronic solutions focusing on healthcare services management. The visit included an introduction to the Health Welfare Information System, a meeting at the Ministry of Social Affairs and a visit to the East Tallin Central Hospital and the Laagri Health Centre.

Estonia is an excellent example that smart decisions and effective execution can have a great impact in healthcare through ICT solutions.



ECPM faculty and participants on their study trip to Estonia.

Education & Training.

Objectives for the coming years.

The objectives of ECPM are to maintain the high quality of the study program, to implement the latest trends and to retain the leading role in the training of Medicines Development.

The ECPM Course is recognized by the Swiss Association of Pharmaceutical Medicine (www.sgpm.ch), by the Swiss Medical Association (www.fmh.ch) and the Swiss Association of Pharmaceutical Professionals (www.swapp.ch) to cover the theoretical training and the examination for specialization and board certification. In addition, the courses are accredited by the Swiss Association of Pharmacists (FPH, www.pharmasuisse.org) for continuing education. We continue to assess further accreditations that substantiate the high quality of the study program.

Collaboration with professional associations and our customers from the pharmaceutical industry, academia and regulatory authorities are key. Therefore our focus remains on strengthening and developing the Master of Advanced Studies to offer the course participants the opportunity to join CPD short courses and acquire credit points, tailored to their needs.

Through the Bologna system it is possible to acquire credit points at other universities. The rule is that at least 50% of the training and the master thesis must be completed at the university where the candidate is enrolled.

The first Master candidate graduated in 2015, with a further 11 candidates completing their degrees between 2018-2023. Several students are

in the process of attending master module courses and writing their master thesis.


Besides the collaboration with the partner universities in Europe, ECPM collaborates internationally with partners that offer courses based on the on the same training syllabus.

Namely the Peking University Clinical Research Institute (PUCRI) at the University of Beijing and the University of California San Francisco to exchange knowledge and enhance training competencies and standards. A number of faculty members teach on all three courses and several students have already switched between the programs due to their changing employment in the global industry.

In 2023 ECPM continued to expand its global footprint by establishing the “Executive Training Program in Drug Development and Regulatory Science” offered by ECPM, Centre for Regulatory Science, Department of Health Information, Prasanna School of Public Health (PSPH), Manipal Academy of Higher Education (MAHE) in India and the Roche India Healthcare Institute. The course was initiated following a request from the former secretary general of EFPIA (European Federation of Pharmaceutical Industries and Associations) Richard Bergström, and facilitated by Professors Angela and Helmut Brand, who hold professorships in public health both in Maastricht, the Netherlands and at PSPH, MAHE, India. Dr Lada Leyens was very instrumental in bridging the initiative since she was working at F. Hoffmann–La Roche in Basel and is holding an endowed chair at PSPH.

Education & Training.

ECPM Training Opportunities



ECPM Certificate and Diploma Course (CAS, DAS) in Pharmaceutical Medicine

The ECPM course is a well-established postgraduate education and training program targeted at representatives from the pharmaceutical industry, service industry, academic and government decision- and policy-makers who already have a good understanding of the basics and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product development, regulation and market introduction.

Course participants are involved in lectures, panel discussions, team-oriented case studies and interactive learning. Participation in the course provides the opportunity to integrate work and education, to discuss with experts face-to-face or online, to gain in-depth knowledge while building an international network, and to put this into perspective with each participant's own career plan.

A faculty network of experts from academia, pharmaceutical and biotechnology companies

and regulatory authorities (including the European Medicines Agency, the Food and Drug Administration, Japanese and Emerging Markets regulatory agencies) carry the teaching responsibility. A successful completion of the course and the final examination provides the title Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine and includes 30 ECTS credits.

Master Course (MAS) in Medicines Development

The Master Course in Medicines Development (MMD) is a postgraduate Master of Advanced Studies course. This program extends the Diploma course in Pharmaceutical Medicine. CPD short courses that count towards the Master, can be chosen according to the needs of the candidates who need to be able to cope with the challenges of drug development. Training and skills provide the basis to critically assess and improve challenges in the drug development process.

The program is designed as an executive course that can be completed in addition to working full or part-time.

Through the IMI PharmaTrain network, we offer the Master of Advanced Studies course participants the opportunity to join courses and acquire credit points, tailored to their needs. Through the Bologna system it is possible to acquire credit points at other universities. The rule is that at least 50 % of the training and the master thesis must be completed at the university where the candidate is enrolled.

Frontiers in Drug Development Seminars

Integrated into the modules of the Diploma course, ECPM offers one-day “Frontiers in Drug Development” seminars on current trends and hot topics. These seminars are open to the public and are accredited for continuing education by different professional organizations, such as the Swiss Medical Association (FMH). The complete list can be viewed on: <http://www.ecpm.ch/frontiers-in-drug-development>.

Examination

The examination was offered onsite at the University of Basel on August 22 and September 12, 2023.

Multiple choice examination (MCQ):

In August, 67 out of 75 candidates passed (i.e. failure rate of 10.7%) and in September, 4 out of 6 candidates passed the examination. The questionnaire consisted of 120 MC questions which included two types of questions. 70 questions were of the “single best answer” type (one out of five possible answers is correct) and 50 questions of the “multiple true false” type (each of the four possible answers has to be rated correct or false).

Eight questions had to be eliminated due to ambiguity which makes a total of 112 possible points.

Oral/Essay examination:

The oral/essay examination was held on August 22 and September 12. This part of the examination is mandatory to achieve the diploma title (DAS). The oral examination is a discussion based on a scientific paper and the essay examination comprises three one page summaries on topics covering clinical development, regulatory affairs or safety/pharmacovigilance. Both the MCQ and the Essay examination were performed on an iPad. One candidate failed the oral/essay in August and one candidate failed in September.

We were able to award 21 CAS and 54 DAS to our participants graduating the flagship course in 2023.

E-learning

To cope with the limited time resources and reduced budgets of specialists working in the health care environment, ECPM has produced three e-learning programs. E-learning modules can be used for different teaching purposes. Firstly they can be used as a self-learning tool for preparation or repetition of the course material, secondly they can replace selected face-to-face modules required to achieve the Master in Medicines Development, and thirdly they enable students to collect credits for Continuing Professional Development (CPD):

- Basics in Health Economics (launched 2013)
- Drug Safety and Pharmacovigilance (launched 2014)
- Personalized Healthcare (launched 2015)
- The Pathway of Drug Development (launched 2021)

A Certificate of Attendance from the University of Basel will be awarded after successful completion of each e-learning program (1 ECTS).

The chapters comprise short lectures with animated slides and quizzes to check the learning outcomes.

Electronic Learning Platform

In 2022, a new electronic training platform containing course documents, videos, books, self-assessments and e-learnings hosted by Cometas was introduced and is now active for the new course cycle.

Education & Training Projects in 2023

- Graduation of the inaugural cohort (16 participants) of ECPM's joint course program with the new Partner University Prasanna School of Public Health, Manipal Academy of Higher Education
- Nomination for the TOPRA 2023 Award in Education – Regulatory Excellence
- Scientific program of the joint annual meeting 2023 of the Swiss Association of Pharmaceutical Professionals and Physicians (SwAPP and SGPM) on “Optimising Patient Engagement and Ensuring Access to Treatment”
- Start of the 17th ECPM diploma course cycle with 108 new participants
- Awarded 21 CAS and 54 DAS to our 2021-23 participants
- Professor Thomas D. Szucs bestowed title of Honorary Professor from Peking University
- Frontiers in Drug Development seminars, “Bringing Medical Devices & Combination Products to the Market”, “Pharmaceutical Pricing and Reimbursement” and “Pharma R&D: Corporate vs Academia
- Contribution to the Update of PharmaTrain Syllabus version 3 regarding regulatory affairs, health economics and new trends & innovation (<https://www.pharmatrain.eu/pharmatrain-syllabus>)

Planned Education & Training Projects for 2024

- Reaccreditation as a PharmaTrain Centre of Excellence
- Working on several new training and teaching programs
- Frontiers in Drug Development seminars, in particular “AI across Drug Discovery and Development”, “Small Clinical Trials, Big Opportunities!” and “The Vital Role of Patients in Shaping Drug Development”
- ECPM representation at the Drug Information Association (DIA) Europe conference in Brussels, Belgium
- Scientific program of the joint annual meeting 2024 of the Swiss Association of Pharmaceutical Physicians (SGPM) and ECPM on “Special Populations in Drug Development and Clinical Care: Across the entire Life Span from Paediatrics to Geriatrics”
- Hosting conference “AI & Digital Health: Demystifying Regulatory Challenges” in collaboration with Casebase Health and Regulatory Thinking
- Participating in the educational panel at SwissBiotech Day.

Expertise for Approval of Radioactive Diagnostics and Therapeutics

Annette Mollet chairs the Federal Expert Committee for radioactive drugs consulting Swissmedic and the Federal Office of Public Health regarding the approval of new diagnostic and therapeutic drugs and tools for nuclear medicine.

PharmaTrain Syllabus working party

Annette participated in the update of the PharmaTrain syllabus being responsible for the regulatory affairs, health economics and future trends & Innovation part.

Undergraduate Teaching at the University of Basel Medical School

1. Szucs TD, Mollet A. Tutorate im Wissenschaftsmonat (WiMo) für Medizinstudenten, 4. / 5. Studienjahr Medizin Master.
2. Szucs TD, Mollet A, Interprofessionelles Modul Medikamentenentwicklung. Major Clinical Medicine, 2. Studienjahr Medizin Bachelor.
3. Szucs TD. Interprofessionelles Modul Pharmakogenomik und personalisierte / individualisierte Medizin. Major Clinical Medicine, 2. Studienjahr Medizin Bachelor.
4. Szucs TD. Ökonomie und Gesundheit (Vorlesung). Major Clinical Medicine, 1. Studienjahr Medizin Bachelor.
5. Szucs TD. Gesundheitsökonomie (Vorlesung), 2. Studienjahr Medizin Master.
6. Schwenkglens M, Lupatsch JE. Interprofessionelles Modul Finanzierung und Vergütung im Schweizer Gesundheitswesen. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
7. Schwenkglens M. Interprofessionelles Modul Gesundheitspolitik – Eine Einführung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
8. Szucs TD. Grundlagen und Übersicht. Einführung in die Medikamentenentwicklung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
9. Szucs TD. Phasen 2 und 3 Prüfungen. Einführung in die Medikamentenentwicklung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
10. Schwenkglens M. Gesundheitsökonomie – Eine Einführung. Part of lecture series Patientenorientierte Evidenz-basierte Medizin (POEM), 3. Studienjahr Medizin Bachelor.
11. Schwenkglens M, Lupatsch JE. Kleingruppenseminare im Themenblock Körper, Subjekt, Umwelt, 1. Studienjahr Medizin Bachelor.

Undergraduate Teaching at the University of Basel, Faculty of Science

1. Schwenkglens M. Lectures forming part of Essentials in Drug Development & Clinical Trials.

Undergraduate Teaching at the University of Zurich

1. Szucs TD, Mollet A. Mantelstudium Arzneimittelentwicklung. 2.–4. Studienjahr Medizin Bachelor, Universität Zürich.
2. Schwenkglens M, Szucs TD, Mollet A. BME310 – Research methodology for studies on human health and disease. 3. Studienjahr Biomedicine Master.
3. Schwenkglens M, Szucs TD. BME318 – Clinical Epidemiology and Quantitative Research in Health Care. 3. Studienjahr Biomedicine Master.

4. Szucs TD, Schwenkglens M, Mollet A. BME329 – Developing New Medicines: An Introduction.
5. 3. Studienjahr Biomedicine Master (responsible PD Dr. Patricia Blank).

Undergraduate Teaching at the University of Bern

1. Schwenkglens M. Lectures on Health economic evaluation and Health Technology Assessment in Switzerland and Europe. Master Biomedical Engineering.

Postgraduate Teaching at the University of Basel

1. Mollet A, Szucs TD, Schwenkglens M. Lectures forming part of the ECPM Course in Pharmaceutical Medicine.
2. Schwenkglens M. Gesundheitsökonomische Modellierung – Hands-on. Course forming part of the Postgraduate Master Program in Public Health.
3. Schwenkglens M. Basics of Health Economic Evaluation. Lecture forming part of CAS Clinical Research II, Module: Advanced Clinical Trial Management.
4. Lupatsch, JE. Bhadhuri. A. Stoffel ST. Barbier M. 41127 Advanced Research Methods – Health Economics, Master and PhD students, Semester course at the Institute of Nursing Sciences.
5. Bhadhuri A. Essentials in Health Research Methodology, Topic 3 – Basics of Health Economics. PhD students, PhD Program Health Sciences (PPHS).

Postgraduate Teaching at the University of Zurich

1. Schwenkglens M. Gesundheitsökonomie. Course forming part of the Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.
2. Schwenkglens M, Szucs TD. Gesundheitsökonomische Evaluation. Course forming part of the Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.
3. Szucs TD. Gesundheitsrecht. Course forming part of Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.

Postgraduate Teaching at the University of Lausanne

1. Schwenkglens M. Key Approaches: Decision-analytic Modelling vs. Within-clinical Trial Cost-effectiveness analysis. Lecture forming part of the SSPH+ Course Introduction to Health Economics.

Research.

Current Status.

The research group at ECPM has maintained its position as one of the most active health economic groups in Switzerland, in terms of publication activity, project scope, and scale, with about 6.5 full-time equivalents of scientific staff.

Recent key developments in 2022/23 were the establishment of the Health Economics Facility (HEF) at the level of the DPH and the foundation of the interfaculty Basel Center for Health Economics (bche), where we join forces with the Health Economics Professorship at the Faculty of Business & Economics and the Household Economics & Health Systems Research Unit at the Swiss TPH. Matthias Schwenkglens is a founding member and co-director of the bche and heads the HEF.

ECPM's research activities started in 2003. Initially, a majority of studies were run with industrial partners, as there was (and is) only limited public funding for pharmaceutical-related health economic evaluation and Health Technology Assessment in Switzerland. In recent years, funding has been achieved in a balanced way from industry, health insurance providers, governmental and semi-governmental organizations and medical collaborative study groups.

We have been and are responsible for the health economic components of various clinical trials and cohort studies, e.g. funded by the European Union and the Swiss State Secretariat for Education, Research and Innovation or the Swiss National Science Foundation. We also take responsibility, since 2007, for the outcomes research and health economic evaluation activities of the Swiss Group for Clinical Cancer Research (SAKK), the leading Swiss collaborative study group in the field of oncology and hematology. Alongside changes to the national approach to Health Technology Assessment (HTA), we are engaged in discussion and are pursuing cooperation with relevant academic and nonacademic players in the field, including health insurance companies. In cooperation with a partner institution at the University of Zurich, we perform HTAs for the Swiss Federal Office of Public Health.

Projects with industrial partners continue to play a relevant role, which gives us opportunities to be involved in HTA activities abroad, e.g. in the UK. In cooperation with the Helsana Group, we have, for the tenth time, published a report on medication utilization in Switzerland, based on health insurance claims data covering about 15 % of the Swiss population (Helsana Arzneimittelreport). Projects and resulting publications are listed in section Overview of Activities, below.

The strategic development of our research activities profits from fruitful exchange within the Department of Public Health of the Medical Faculty. We pursue and intensify our cooperation with other units at the University of Basel pursuing related research activities, e.g. the Faculty of Business and Economics, Swiss Tropical and Public Health Institute, Institute of Nursing Sciences, Department of Clinical Epidemiology, and Basel Pharmacoepidemiology Unit.

Key Areas of Expertise

- Variation in healthcare utilization
- Medication utilization in Switzerland
- Approaches to health technology assessment
- Efficiency and value of health care services

Research is done in the following therapeutic areas: Oncology and hematology, cardiovascular disease and heart failure, neurology, influenza and other infectious diseases, geriatrics, specifically pharmacotherapy optimization in the elderly and palliative care.

Research.

Objectives for the coming years.

The situation and achievements of ECPM in 2023 reflect the continued, successful development of a small research unit. In the coming years, we will seek to maintain a sensible balance of competitively (EU, potentially SNSF), publicly and privately funded research projects. As third-party funding of Health Technology Assessment-related and health economic evaluation-related research remains structurally uncertain, we also need to gain substantially more long-term university funding for our research group to ensure sustainability.

In the context, the establishment of the HEF and the bche were key developments. For 2024, we plan for continued 'next-level' development of ECPM's research activities by further integration

with these organizational units. One key aim is the further development of HEF strategy and, mediated through the HEF, the anchoring of health economics and health services research in the Medical Faculty. There are planned contributions to shaping the research strategy of the Department of Public Health. From a scientific perspective, we also plan to further extend our activities in trial-based cost-effectiveness analyses (e.g. addressing methodological issues around international trials, approaches to missing values) and causal inference methods applied to real-world data (e.g. health insurance data), health services research and behavioral economics. Decision-analytic modelling remains a strong cornerstone.



The ECPM participants attentively following the session in the main lecture hall of the Biozentrum.

Research.


Overview of activities.

Sources of incoming funding 2023



Running activities during 2023 KCHF 780

University core funding	9%
University Hospital Basel	2%
Other Hospitals	4%
European Union	6%
Swiss National Science Foundation, Innosuisse	17%
Federal Office of Public Health	8%
Health Promotion Switzerland	9%
Insurance companies	12%
Industry	30%
Miscellaneous	3%
Total	100%



New acquisitions, KCHF 920

University core funding	8%
University research fund	7%
University Hospital Basel	3%
Other Hospitals	2%
European Union	31%
Federal Office of Public Health	18%
Insurance companies	10%
Industry	20%
Miscellaneous	1%
Total	100%

Recent and current projects were/are with the following partners:

Basel University Hospitals

- Dr Lut Berben (University Children's Hospital Basel)
- PD Dr Julia Bielicki (University Children's Hospital Basel)
- PD Dr Salome Dell-Kuster (University Hospital Basel, Anaesthesiology)
- PD Dr Elisabeth A. Kappos (University Hospital Basel, Surgery)
- Prof Stefan Osswald, Prof Michael Kühne, Prof Christian Sticherling (University Hospital Basel, Cardiology)
- Dr Florian Rüter (University Hospital Basel, Quality Management)
- Prof Rainer Schäfer, Prof Gunther Meinlschmidt (University Hospital Basel, Psychosomatic Medicine)
- Prof Walter Weber (University Hospital Basel, Surgery)
- PD Dr Özgür Yaldizli, PD Dr Lars Hemkens (University Hospital Basel, Neurology and Research Center for Clinical Neuroimmunology and Neuroscience RC2NB)

University of Basel and Swiss Tropical and Public Health Institute (Swiss TPH)

- Prof Sabina De Geest (Department of Public Health)
- Prof Stefan Felder (Faculty of Business and Economics)
- Prof Günther Fink (Swiss TPH, Faculty of Business and Economics)
- Prof Ivan Martin (Department of Biomedicine)
- Prof Christoph R. Meier (Department of Pharmaceutical Sciences)
- Prof Beat Müller (Department of Clinical Research, Cantonal Hospital Aarau)
- Prof Nicole Probst-Hensch (Swiss TPH)
- Prof Kaspar Wyss (Swiss TPH)
- University of Basel Innovation Office

National and international academic units and collaborative study groups

- Prof Christina Andreou, CHUV Lausanne
- Prof Steffen Eychmüller, University Center for Palliative Care, University Hospital Bern
- Prof Hendrik Fuchs, Charité – Universitätsmedizin Berlin, Germany
- Dr Yasemin Hirst, Applied Health Research Hub, University of Central Lancashire, UK
- Dr Paola Mantellini, Dr Giuseppe Gorini, Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO), Firenze, Italy
- Prof Mark Pletscher, Prof Tobias Müller, Institute for Health Economics and Health Policy, University of Applied Sciences Bern
- Prof Milo Puhan, Dr Miquel Serra-Burriel, Epidemiology, Biostatistics and Prevention Institute, University of Zürich
- Prof Nicolas Rodondi, Prof Sven Streit, Institute of Primary Health Care (BIHAM), University of Bern
- Prof Thomas Rosemann, Institute of Primary Care Medicine, University of Zürich
- Swiss Group for Clinical Cancer Research, Bern
- Prof Roger von Moos, Department of Oncology, Cantonal Hospital Graubünden
- Dr Christian von Wagner, Research Department of Behavioural Sciences and Health, University College London, UK
- Prof Ivo Vlaev, Warwick Business School, Warwick University, UK

- Prof Simon Wieser, Winterthur Institute of Health Economics, ZHAW Zurich University of Applied Sciences
- Dr Jan Wollgast, Joint Research Centre (JRC), European Commission, Ispra, Italy

Public entities

- Gesundheitsdepartement des Kantons Basel Stadt, MSc Anja Studer, MSc Christina Karpf (Medizinische Dienste, Abteilung Prävention)
- Health Promotion Switzerland, Bern
- Swiss Federal Office of Public Health, Bern
- Swiss Medical Board, Bern (active until 2023)

Private entities

- Pharmaceutical Companies
- Insurance Companies
- German Breast Group, Neu-Isenburg, Germany



During the coffee break, ECPM participants networking, exchanging ideas and building valuable professional connections.

Research.

Upcoming Projects: outlook 2024.

New

Title:	Quality of life (QoL) versus length of life (LoL)
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	To investigate in a longitudinal survey whether patients with gastric cancer change their preferences for QoL vs LoL during their treatment
Start date:	expected 2024
Partner(s):	Dr Mickael Chaevallay (HUG), Swiss Group for Clinical Cancer Research (SAKK)
Output:	Pending
Source of funding:	Swiss Cancer Research

New

Title:	Enhancing palliative Care in ICU (EPIC)
Project lead & contributors:	MS, MB
Hypothesis / Objectives:	The EPIC project implements a harmonized palliative care practice model for the ICU (the EPIC model)a multicentre randomised clinical trial to document the effectiveness of the EPIC model substudies to strengthen and refine the EPIC model for sustainability a social science and humanities approach to develop ethical guidelines for the European civic society. Within EPIC, ECPM is responsible for the health economic part of the clinical trial
Start date:	01/2024
Partner(s):	Charité Universitätsmedizin Berlin, Germany; partners of the EPIC consortium
Output:	Pending
Source of funding:	EU HORIZON Europe: European Union / Swiss State Secretariat for Education, Research and Innovation

New

Title:	Accompanying research Réseau de l'Arc
Project lead & contributors:	MS, MB, SM
Hypothesis / Objectives:	The Basel Center for Health Economics (BCHE), with its member organization ECPM, and the Swiss Tropical and Public Health Institute (Swiss TPH), will be studying the integrated care model Réseau de l'Arc over several years. The aim is to assess its impact on various qualitative, quantitative and economic aspects of healthcare, including efficiency and the development of care costs
Start date:	03/2024
Partner(s):	Faculty of Business and Economics, Swiss TPH, Réseau de l'Arc, Swiss Medical Network, Visana
Output:	Pending
Source of funding:	Integrated care organization

New

Title:	CIBOSurg
Project lead & contributors:	DS, STS, MS
Hypothesis / Objectives:	The CIBOSurg project is a quality improvement and implementation project wherein a structured recording of intraoperative complications is performed and discussed at the end of surgery, using the ClassIntra® tool. This intervention is expected to improve surgical outcomes and reduce preventable post-surgical events. Within CIBOSurg, ECPM is responsible for the health economic part
Start date:	03/24
Partner(s):	Prof Dell-Kuster, USB
Output:	Pending
Source of funding:	Stiftung Anästhesiologie und Intensivmedizin, Eidgenössische Qualitätskommission (EQK)

Research.

New Projects (started in 2023).

New	
Title:	The LYMPHTrial - Surgical versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema: A Pragmatic, Randomized, Multicenter Superiority Trial
Project lead & contributors:	JL, MS
Hypothesis / Objectives:	Primary Objective The primary objective of this trial is to test whether lymphatic surgery provides better quality of life (assessed with the Lymph-ICF-UL, upper limb, questionnaire) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema. Within LYMPH, ECPM is responsible for the health economic part
Start date:	07/2023
Partner(s):	Prof Elisabeth Artemis Kappos (USB)
Output:	Pending
Source of funding:	Swiss National Science Foundation
New	
Title:	PFOA
Project lead & contributors:	DS, MS
Hypothesis / Objectives:	PFOA II is a Phase II clinical trial wherein a nasal cartilage graft is harvested from a patient with knee osteoarthritis and grown to sufficient size in a tissue laboratory, and then transplanted to repair large defects in the patella of the same patient. The comparator is intra-articular joint injection of platelet-rich plasma. Within PFOA II, ECPM is responsible for the health economic part. A cost-utility analysis will be performed, and it is hypothesized that the intervention is cost-effective in the long term, considering the potential cost savings for avoiding knee replacement surgery, rehabilitation, complications, as well as improving function, reducing pain, and higher quality of life.
Start date:	09/2023
Partner(s):	PD Dr Marcus Mumme, USB; Prof Ivan Martin, Department of Biomedicine
Output:	Pending
Source of funding:	Swiss National Science Foundation
New	
Title:	Datensatz und Auswertung von Rohdaten der Pilotversuche mit Cannabis in der Schweiz 2023–2025
Project lead & contributors:	STS, MB, NSch, MS
Hypothesis / Objectives:	To combine data from cannabis pilot studies to analyse the impact of participating in them on health and cannabis use
Start date:	11/2023
Partner(s):	Swiss Federal Office of Public Health
Output:	Pending
Source of funding:	Swiss Federal Office of Public Health

New

Title:	A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
Project lead & contributors:	JL, MS
Hypothesis / Objectives:	Due to the lack of effective targeted treatment options, docetaxel was the standard second line therapy for patients with advanced NSCLC, including the Kirsten rat sarcoma virus (KRAS) G12C mutation, for a long time. The CodeBreak 200 trial demonstrated a modest improvement in progression-free survival (PFS) with sotorasib, a new drug targeting the G12C mutated K-RAS protein, over docetaxel in patients who had progressed after first-line treatment with platinum and programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors. Consequently, sotorasib received temporary approval in Switzerland. Our analysis aimed to assess the cost-effectiveness of sotorasib as a second-line treatment in Swiss NSCLC patients from the Swiss statutory health insurance system perspective
Start date:	08/2023
Partner(s):	Kantonsspital Graubünden
Output:	Pending
Source of funding:	Kantonsspital Graubünden



Participants of the ECPM CAS/DAS connecting and sharing insights over refreshments during the break.

Research.

Ongoing projects.

Ongoing

Title:	PsyYoung economic analysis
Project lead & contributors:	DS, MS
Hypothesis / Objectives:	Estimate the cost in Switzerland of facilitating access to care for young people at risk for psychotic disorders
Start date:	01/2022
Partner(s):	Prof. Dr. Christina Andreou, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
Output:	Pending
Source of funding:	CHUV

Ongoing

Title:	Cost data of patients dying in the hospital: does Palliative Care matter?
Project lead & contributors:	MS, MB
Hypothesis / Objectives:	The retrospective study's primary objective is calculate hospital costs of patients who died at University Hospital Bern (Inselspital) between 2016–2020. The overall hospital costs of patients who received palliative care are compared with the costs of those who received usual care (UC). Additionally, the study assesses the role of different types of palliative care patients, and of different cost types. ECPM supports the partner at University Hospital Bern with expertise in cost analysis and related aspects.
Start date:	09/2022
Partner(s):	University Centre for Palliative Care, University Hospital Bern
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Cost-utility analyses of immunotherapy drug for different cancers
Project lead & contributors:	JL, AB, NSch
Hypothesis / Objectives:	The aim of this study is to evaluate the cost-effectiveness of pembrolizumab for (a) patients with renal cell carcinoma post-nephrectomy (versus observation) and (b) patients with triple negative breast cancer (versus chemotherapy alone) in Switzerland.
Start date:	06/2022
Partner(s):	Industry
Output:	Manuscripts submitted
Source of funding:	Industry

Ongoing

Title:	SPEARHEAD: Fighting Antimicrobial resistance through rapid digital pandemic response
Project lead & contributors:	ML, JL, MS
Hypothesis / Objectives:	To contribute to optimised practices in managing antimicrobial resistance (AMR) that may easily be harnessed to address future emerging infections. ECPM is responsible for developing a conceptual model including the reasons and consequences of AMR and for performing the cost-effectiveness of a novel diagnostic which substantially reduces the time to results of an antibiotic susceptibility test, compared with currently used technologies.
Start date:	01/2022
Partner(s):	Consortium of 8 public and 4 private Swiss institutions
Output:	Pending
Source of funding:	Innosuisse

Ongoing

Title:	Herding-like behavior
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	The experimental study investigates to what extent do primary care physicians follow prescription recommendations of their peers.
Start date:	09/2022
Partner(s):	University of Warwick (UK)
Output:	https://pubmed.ncbi.nlm.nih.gov/38976681/
Source of funding:	Biäsch Stiftung

Ongoing

Title:	DepRescribing inapprOpriate Proton Pump InibiTors (DROPIT) trial
Project lead & contributors:	MB, MS
Hypothesis / Objectives:	The trial aims to investigate the effectiveness of an intervention for adult patients and general practitioners to deprescribe inappropriate proton pump inhibitor use. ECPM is responsible forevaluating the cost-effectiveness of the trial intervention
Start date:	09/2022
Partner(s):	BIHAM (Institute of Primary Health Care). University of Bern
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	MultiSCRIPT –Treatment Optimization in Multiple Sclerosis
Project lead & contributors:	MS, ML, KG
Hypothesis / Objectives:	The platform trial MultiSCRIPT investigates how intensive monitoring of biomarkers can improve patient-relevant outcomes as well as the care of MS patients. Within MultiSCRIPT, ECPM is responsible for the health economic part
Start date:	11/2022
Partner(s):	Universitätsspital Basel, Departement Klinische Forschung, Inselspital, L'Ente Ospedaliero Cantonale
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Value-based Health Care Data analysis on lung cancer costs and patient-reported outcomes
Project lead & contributors:	MB, KG, ML, MS
Hypothesis / Objectives:	To develop an algorithm to merge administrative datasets from Basel University Hospital covering services and billings with patient-reported and clinician-reported outcome measures for lung cancer patients treated at the Hospital, analyze the linked datasets to identify treatment patterns and relate these to patient outcomes and costs toward optimal care pathways
Start date:	10/2021
Partner(s):	University Hospital Basel, Industry
Output:	Pending
Source of funding:	University Hospital Basel, Industry

Ongoing	
Title:	Pre- versus sub-pectoral implant-based breast reconstruction after nipple-sparing mastectomy (OPBC-02 PREPEC): A pragmatic, multicenter, randomized, superiority trial
Project lead & contributors:	JL, MS
Hypothesis / Objectives:	Within PREPEC, ECPM is responsible for establishing health economic properties of the compared surgical techniques
Start date:	07/2019
Partner(s):	Prof. Walter Paul Weber, Klinik für Allgemeinchirurgie, Universitätsspital Basel
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing	
Title:	Drug utilization reports based on Swiss health insurance claims data
Project lead & contributors:	NSch, MS
Hypothesis / Objectives:	Analysis of drug use in Switzerland and related medical and economic aspects, based on Swiss health insurance data
Start date:	09/2013
Partner(s):	Basel Pharmacoepidemiology Unit and Hospital Pharmacy, University Hospital Basel
Output:	https://reports.helsana.ch/arzneimittel2022/
Source of funding:	Health insurance provider

Ongoing	
Title:	Co-operative projects with the SAKK in the field of health economics and outcomes research in oncology
Project lead & contributors:	JL, STS, MS
Hypothesis / Objectives:	Outcomes research, health services research and health economic evaluation projects in cooperation with Swiss Group for Clinical Cancer Research (SAKK) and hospitals
Start date:	11/2007
Partner(s):	SAKK, University Hospital Basel, other hospitals
Output:	Abstracts, peer-reviewed publications. https://doi.org/10.4414/smw.2021.20464
Source of funding:	SAKK

Ongoing	
Title:	The indirect costs of oesophageal cancer in Switzerland
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	To identify the indirect costs (i.e. productivity loss, informal care) of oesophageal cancer in Switzerland.
Start date:	10/2021
Partner(s):	Industry
Output:	Pending
Source of funding:	Industry

Ongoing

Title:	Are we offering BRCA1/BRCA2 testing to the right women in Switzerland? Cost-effectiveness of the BRCA genetic testing threshold
Project lead & contributors:	JL
Hypothesis / Objectives:	To assess the current testing practice in Switzerland & establish cost-effectiveness for Switzerland
Start date:	01/2019
Partner(s):	University Hospital Zurich, University Hospital Geneve, University Hospital Lausanne, Swiss Group for Clinical Cancer Research (SAKK)
Output:	Report
Source of funding:	Swiss Cancer Research

Ongoing

Title:	Evaluation project alongside a prevention project on somatoform disorders
Project lead & contributors:	NSch, MS
Hypothesis / Objectives:	Formative, outcome and impact evaluation of project: «Prävention psychosozialer Belastungsfolgen in der Somatik: ein Modellprojekt zur kollaborativen Versorgung (SomPsyNet)»
Start date:	03/2019
Partner(s):	University Hospital Basel, Swiss Tropical and Public Health Institute
Output:	Internal reports; https://pubmed.ncbi.nlm.nih.gov/35592378/ ; https://doi.org/10.1186/s12888-021-03353-5
Source of funding:	Health Promotion Switzerland



Seminar on AI in Drug Development in the series of «Frontiers in Drug Development».

Research.

Completed projects.

Completed	
Title:	Cost-effectiveness and budget impact analysis for patients with mesothelioma
Project lead & contributors:	MB
Hypothesis / Objectives:	Investigate cost-effectiveness and budget impact within the current Swiss treatment landscape
Start date:	06/2021
Partner(s):	Swiss National Accident Insurance Fund (SUVA), Cantonal Hospital Lucerne
Output:	https://pubmed.ncbi.nlm.nih.gov/37572261/
Source of funding:	SUVA

Completed	
Title:	Evaluation project alongside a project on falls prevention
Project lead & contributors:	NSch, MS
Hypothesis / Objectives:	Formative, outcome and impact evaluation of project: «Sturzprävention in der Gesundheitsversorgung – Überführung in die Regelversorgung (StoppSturz)»
Start date:	03/2019
Partner(s):	Swiss Tropical and Public Health Institute
Output:	Internal reports
Source of funding:	Health Promotion Switzerland

Completed	
Title:	Survey to identify drivers and barriers towards pneumococcal vaccination
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	To identify drivers and barriers towards pneumococcal vaccination in adult risk groups in Switzerland
Start date:	01/2021
Partner(s):	Industry
Output:	https://pubmed.ncbi.nlm.nih.gov/36175212/
Source of funding:	Industry

Completed	
Title:	Health economic aspects of atrial fibrillation: analysis based on the Swiss-AF cohort study
Project lead & contributors:	MS
Hypothesis / Objectives:	Study of health economic implications of atrial fibrillation and health economic properties of related treatments
Start date:	04/2019
Partner(s):	Cardiology, University Hospital Basel; Epidemiology, Biostatistics and Prevention Institute, University of Zürich
Output:	https://data.snf.ch/grants/grant/189195
Source of funding:	Swiss National Science Foundation

Completed

Title:	ENDOSCAPE, a clinically applicable non-viral gene delivery technology
Project lead & contributors:	STS, KG, NM, MS
Hypothesis / Objectives:	The non-viral-based ENDOSCAPE technology aims to enhance the efficacy of gene therapies with lower therapeutic dose thereby reducing costs of healthcare, improving the health of patients worldwide, and strengthening the competitive landscape of the EU in the worldwide quest for such an advanced technology. Within the ENDOSCAPE project, ECPM has performed early health economic evaluation studies
Start date:	01/2019
Partner(s):	ENDOSCAPE Consortium: Sapreme Technologies BV, Holland, Max-Planck-Gesellschaft zur Förderung der Wissenschaften EV, Germany, VIB Belgien, Freie Universität Berlin, Germany, Universidad de Santiago de Compostela, Spain, Università degli Studi di Roma Tor Vergata, Italy, Extrasynthese SAS, France, Università degli Studi di Ferrara, Italy, Universität Schweiz, Switzerland, TP21 GmbH, Germany
Output:	Internal reports
Source of funding:	EU (HORIZON 2020, grant agreement 825730)



The Biozentrum at the University of Basel offers a modern and dynamic setting for the ECPM post-graduate course, where innovation meets advanced learning.

Activities of the ECPM collaborators in 2022.

Publications, Scientific Presentations, Evaluation of Research Projects and Thesis Supervision.

1. Zay Ya K, Win PTN, Bielicki J, **Lambiris M***, Fink G*. Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. *JAMA Netw Open*. 2023 Feb 1;6(2):e2253806. doi: 10.1001/jamanetworkopen.2022.53806. <https://pubmed.ncbi.nlm.nih.gov/36757700/>
* Shared last authorship.
2. **Lambiris MJ**, Venga GN, Ssempala R, Balogun V, **Galactionova K**, Musiitwa M, Kagwire F, Olosunde O, Emedo E, Luketa S, Sangare M, Buj V, Delvento G, Tshetu A, Okitawutshu J, Omoluabi E, Awor P, Signorell A, Hetzel MW, Lee TT, Brunner NC, Cereghetti N, Visser T, Napier HG, Burri C, Lengeler C. Health system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints. *Lancet Glob Health*. 2023 Feb;11(2):e256-e264. doi: 10.1016/S2214-109X(22)00507-1. <https://pubmed.ncbi.nlm.nih.gov/36565705/>
3. Hetzel MW, Okitawutshu J, Tshetu A, Omoluabi E, Awor P, Signorell A, Kwiatkowski M, **Lambiris MJ**, Visser T, Cohen JM, Buj V, Burri C, Lengeler C. Pre-referral rectal artesunate is no “magic bullet” in weak health systems. *BMC Med*. 2023 Mar 30;21(1):119. doi: 10.1186/s12916-023-02777-y. PMID: 36991404; PMCID: PMC10060914. pubmed.ncbi.nlm.nih.gov/36991404/
4. Hetzel MW, Awor P, Tshetu A, Omoluabi E, Burri C, Signorell A, **Lambiris MJ**, Visser T, Cohen JM, Buj V, Lengeler C. Pre-referral rectal artesunate: no cure for unhealthy systems. *Lancet Infect Dis*. 2023 Jun;23(6):e213-e217. doi: 10.1016/S1473-3099(22)00762-9. Epub 2022 Dec 19. pubmed.ncbi.nlm.nih.gov/36549311/
5. Brunner NC, Karim A, Athieno P, Kimera J, Tumukunde G, Angiro I, Signorell A, Delvento G, Lee TT, **Lambiris M**, Ogwal A, Nakiganda J, Mpanza F, Kagwire F, Amutuhaire M, Burri C, Lengeler C, Awor P, Hetzel MW. Starting at the community: Treatment-seeking pathways of children with suspected severe malaria in Uganda. *PLOS Glob Public Health*. 2023 Jul 5;3(7):e0001949. doi: 10.1371/journal.pgph.0001949. <https://pubmed.ncbi.nlm.nih.gov/37405978/>
6. **Barbier MC**, Fengler A, Pardo E, **Bhadhuri A**, **Meier N**, Gautschi O. Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland. *Pharmacoeconomics* 2023;41:1641-1655. doi: 10.1007/s40273-023-01305-3. <https://pubmed.ncbi.nlm.nih.gov/37572261/>
7. Meinschmidt G, Frick A, Baenteli I, Karpf C, Studer A, Bachmann M, Dörner A, Tschudin S, Trost S, Wyss K, Fink G, **Schwenkglens M**, Caviezel S, Rocco T, Schaefer R; SomPsyNet consortium. Prevention of psychosocial distress consequences in somatic hospital inpatients via a stepped and collaborative care model: protocol of SomPsyNet, a stepped wedge cluster randomised trial. *BMJ Open* 2023;13:e076814. doi: 10.1136/bmjopen-2023-076814. <https://pubmed.ncbi.nlm.nih.gov/37996236/>

8. Foster-Witassek F, Aebersold H, Aeschbacher S, Ammann P, Beer JH, Blozik E, Bonati LH, Cattaneo M, Coslovsky M, Felder S, Moschovitis G, Müller A, Netzer S, Paladini RE, Reichlin T, Rodondi N, Stauber A, Sticherling C, **Szucs T**, Conen D, Kühne M, Osswald S, Serra-Burriel M, **Schwenkglens M**; Swiss-AF Investigators. Longitudinal Changes in Health-Related Quality of Life in Patients With Atrial Fibrillation. *J Am Heart Assoc* 2023;12:e031872. doi: 10.1161/JAHA.123.031872.
<https://pubmed.ncbi.nlm.nih.gov/37929709/>
9. Serra-Burriel M, Aebersold H, Foster-Witassek F, Coslovsky M, Rodondi N, Blum MR, Sticherling C, Moschovitis G, Beer JH, Reichlin T, Krisai P, Aeschbacher S, Paladini RE, Kühne M, Osswald S, Conen D, Felder S, **Schwenkglens M**, for the Swiss-AF investigators. Real-world cost-effectiveness of pulmonary vein isolation for atrial fibrillation: a target trial approach. *Value Health* 2023;26:1721-1729. doi: 10.1016/j.jval.2023.08.008.
<https://pubmed.ncbi.nlm.nih.gov/37741443/>
10. Aebersold H, Foster-Witassek F, Serra-Burriel M, Brüngger B, Aeschbacher S, Beer JH, Blozik E, Blum MR, Bonati LH, Conen D, Conte G, Felder S, Huber C, Kühne M, Moschovitis G, Müller A, Paladini R, Reichlin T, Rodondi N, Springer A, Stauber A, Sticherling C, **Szucs T**, Osswald S, **Schwenkglens M**, on behalf of the Swiss-AF Investigators. Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls. *BMJ Open* 2023;13:e072080. doi: 10.1136/bmjopen-2023-072080.
<https://pubmed.ncbi.nlm.nih.gov/37709325/>
11. Aebi NJ, Baenteli I, Fink G, Meinschmidt G, Schaefer R, **Schwenkglens M**, Studer A, Trost S, Tschudin S, Wyss K; SomPsyNet Consortium. Facilitators and barriers of routine psychosocial distress assessment within a stepped and collaborative care model in a Swiss hospital setting. *PLoS One* 2023;18:e0285395. doi: 10.1371/journal.pone.0285395.
<https://pubmed.ncbi.nlm.nih.gov/37390066/>
12. **Stoffel ST**, **Schwenkglens M**, Mutschler T. General Practitioners' Awareness and Perception of Current Pneumococcal Vaccination for Adult Patients with Known Risk Factors in Switzerland: Evidence from a Survey. *Vaccines (Basel)* 2023;11:1101. doi: 10.3390/vaccines11061101.
<https://pubmed.ncbi.nlm.nih.gov/37376490/>
13. Pinsent A, Weston G, Adams EJ, Linley W, Hawkins N, **Schwenkglens M**, Hamlyn-Williams C, Toward T. Determining the Relationship Between Seizure-Free Days and Other Predictors of Quality of Life in Patients with Dravet Syndrome and Their Carers from FFA Registration Studies. *Neurol Ther* 2023;12:1593-1606. doi: 10.1007/s40120-023-00510-8.
<https://pubmed.ncbi.nlm.nih.gov/37328668/>
14. Moutzouri E, Glutz M, Abolhassani N, Feller M, Adam L, Gencer B, Del Giovane C, Bétrisey S, Paladini RE, Hennings E, Aeschbacher S, Beer JH, Moschovitis G, Seiffge D, De Marchis GM, Coslovsky M, Reichlin T, Conte G, Sinnecker T, **Schwenkglens M**, Bonati LH, Kastner P, Aujesky D, Kühne M, Osswald S, Fischer U, Conen D, Rodondi N. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study. *Int J Stroke* 2023;17474930231181010. doi: 10.1177/17474930231181010.
pubmed.ncbi.nlm.nih.gov/37243540/

15. Jungo KT, Ansorg AK, Floriani C, Rozsnyai Z, Schwab N, **Meier R**, Valeri F, Stalder O, Limacher A, Schneider C, Bagattini M, Trelle S, Spruit M, **Schwenkglens M**, Rodondi N, Streit S. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. *BMJ* 2023;381:e074054. doi: 10.1136/bmj-2022-074054. <https://pubmed.ncbi.nlm.nih.gov/37225248/>
16. Sibille FX, de Saint-Hubert M, Henrard S, Aubert CE, Goto NA, Jennings E, Dalleur O, Rodondi N, Knol W, O'Mahony D, **Schwenkglens M**, Spinewine A. Benzodiazepine Receptor Agonists Use and Cessation Among Multimorbid Older Adults with Polypharmacy: Secondary Analysis from the OPERAM Trial. *Drugs Aging* 2023;40(6):551-561. doi: 10.1007/s40266-023-01029-1. pubmed.ncbi.nlm.nih.gov/37221407/
17. Roos J, Schürch D, Frei A, Lagger S, **Schwenkglens M**, Vogt A, Herzig D, Bally L. Time requirements for perioperative glucose management using fully closed-loop versus standard insulin therapy: A proof-of-concept time-motion study. *Diabet Med* 2023:e15116. doi: 10.1111/dme.15116. <https://pubmed.ncbi.nlm.nih.gov/37052409/>
18. **Salari P**, Henrard S, O'Mahony C, Welsing P, **Bhadhuri A**, Jungo KT, Beck T, O'Mahony D, Byrne S, Spinewine A, Knol W, Rodondi N, **Schwenkglens M**. Healthcare Costs and Health-Related Quality of Life in Older Multimorbid Patients After Hospitalization. *Health Serv Insights* 2023;16:11786329231153278. doi: 10.1177/11786329231153278. pubmed.ncbi.nlm.nih.gov/36760460/
19. Favre-Bulle A, Bencina G, Zhang S, Jiang R, Andritschke D, **Bhadhuri A**. Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. *J Med Econ* 2023;26:283-292. doi: 10.1080/13696998.2023.2174748. PMID: 36748342 Free article. <https://pubmed.ncbi.nlm.nih.gov/36748342/>
20. Aebersold H, Serra-Burriel M, Foster-Wittassek F, Moschovitis G, Aeschbacher S, Auricchio A, Beer JH, Blozik E, Bonati LH, Conen D, Felder S, Huber CA, Kuehne M, Mueller A, Oberle J, Paladini RE, Reichlin T, Rodondi N, Springer A, Stauber A, Sticherling C, **Szucs TD**, Osswald S, **Schwenkglens M**. Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort. *Heart* 2023;109:763-770. doi: 10.1136/heartjnl-2022-321520. <https://pubmed.ncbi.nlm.nih.gov/36332981/>
21. **Stoffel, S. T.**, Sun, Y., Hirst, Y., von Wagner, C., Vlaev, I. (2023). Testing the decoy effect to improve online survey response: Evidence from a field experiment. *Journal of Behavioral and Experimental Economics*, 107, 102103. <https://doi.org/10.1016/j.socec.2023.102103>
22. Cook, B., Costa Leite, J., Rayner, M., **Stoffel, S.**, van Rijn, E., & Wollgast, J. (2023). Consumer Interaction with Sustainability Labelling on Food Products: A Narrative Literature Review. *Nutrients*, 15(17), 3837. doi.org/10.3390/nu15173837

23. Gorini, G., Betti, E., **Stoffel, S.**, Falini, P., Iossa, A., Senore, C., Baiocchi, C., Zappa, M., Battisti, F., & Mantellini, P. (2023). Testing behavioral economics messages to increase non-responders' participation in organized colorectal cancer-screening programs: A randomized controlled trial. *Preventive Medicine*, 107615. <https://doi.org/10.1016/j.ypmed.2023.107615>
24. Hirst, Y., **Stoffel, S. T.**, Wang, W., Brewer, H., Timotijevic, L., Raats, M., Flanagan, J. (2023). Understanding Public Attitudes and Willingness to Share Commercial Data for Health Research: A Survey Study in the United Kingdom. *JMIR Public Health and Surveillance*. 9:e40814 <https://doi.org/10.2196/40814>
25. Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, Weiss M, Pletscher **M**, **Meier N**. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. *Swiss Medical Weekly*. 2023;153(9):s3441. doi: <https://doi.org/10.57187/s.3441> <https://pubmed.ncbi.nlm.nih.gov/37774383/>
26. Aebersold H, Foster-Witassek F, Aeschbacher S, Beer JH, Blozik E, Blum M, Bonati L, Conte G, Coslovsky M, De Perna ML, Di Valentino M, Felder S, Huber CA, Moschovitis G, Mueller A, Paladini RE, Reichlin T, Rodondi N, Stauber A, Sticherling C, **Szucs TD**, Conen D, Kuhne M, Osswald S, **Schwenkglens M**, Serra-Burriel M; Swiss-AF Investigators. Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort. *Open Heart*. 2024 Jan 31;11(1):e002567. doi: 10.1136/openhrt-2023-002567.



Over 100 ECPM participants and faculty gathered at the Biozentrum, University of Basel, for a memorable group photo, marking a successful collaboration and shared learning experience.

Scientific Presentations to External Audiences

Presenter (name, function)	Presentation title	Event (title, location)	Date
Szucs TD, Director	Systematic Reviews and Its Role in Development of Clinical Practice Guideline – CCDRS Course Module 3	University of Peking	18.08.23
Szucs TD, Director	Patient-Reported Outcomes and Quality of Life Measurements – CCDRS Course Module 3	University of Peking	18.08.23
Szucs TD, Director	Choice of Endpoints: Continuous, Dichotomous, Composite and Survival – CCDRS Course Module 3	University of Peking	18.08.23
Szucs TD, Director	Demystifying Industry-Academia Collaboration Seminar ECPM	University of Basel	31.08.23
Szucs TD, Director	A History of Drug Discovery and Research – Module 1, European Course of Pharmaceutical Medicine	University of Basel	28.08.23
Szucs TD, Director	Health Care Systems in Transition: Challenges for the Drug Developer – Module 1, European Course of Pharmaceutical Medicine,	University of Basel	28.08.23
Szucs TD, Director	Sport und Gene	Hofwiesbad	01.09.23
Szucs TD, Director	Genomische Medizin und ihre Bedeutung für die Gynäkologie – Fortbildung Gyn-Health	Zürich	05.09.23
Szucs TD, Director	How to write an abstract. BME310, Research methodology for studies on human health and disease	UZH	19.09.23,
Szucs TD, Director	Epidemiological study designs, BME310, Research methodology for studies on human health and disease.	UZH	19.09.23
Szucs TD, Director	Genomics, Personalized Medicine and Innovation; International Federation of Health Plans, Executive Education Session	Zurich	25.09.23
Szucs TD, Director	Principles of Post Marketing Safety and Pharmacovigilance, CCDRS	Beijing	09.10.23
Szucs TD, Director	Pharmacoeconomics – an Introduction, CCDRS	Beijing	10.10.23
Szucs TD, Director	Gesundheitswesen am Scheideweg: Neue Technologien zwischen Heilung und Kontroverse.	Ringvorlesung UZH	24.10.23
Szucs TD, Director	Research using real world data in health insurance. CAS der ETH «Modern concepts in clinical research».	ETH Zürich	16.11.23
Matthias Schwenkglens Head of Research	Integrating Health Economic Evaluation into Clinical trials – ESTS Women in General Thoracic Surgery Academy	Online Vortrag	07.03.23

Matthias Schwenkglens Head of Research	Establishing Value-for-Money of Health Interventions	Vortrag, Basel Center for Health Economics Inaugural Event	13.09.23
Annette Mollet Head of Education & Training	Online course Executive Training Program in Drug Development and Regulatory Science in collaboration with PRASANNA SCHOOL OF PUBLIC HEALTH at MAHE	Manipal, India	24.02.23 – 26.11.23
Annette Mollet Head of Education & Training	TOPRA Awards for Regulatory Affairs 2023;	London	29.10.23
Annette Mollet Head of Education & Training	Regulatory Affairs, BME 329, Developing New Medicines – An Introduction	University of Zurich	30.03.23
Annette Mollet Head of Education & Training	Module 5 Regulatory Writing during Global Registration and Approval Process	University of Zurich	06.02.23 – 09.02.23
Annette Mollet Head of Education & Training	Development of Medicines, BME310 – Research methodology for studies on human health and disease,	University of Zurich	22.09.23
Annette Mollet Head of Education & Training	ECPM Advisory Board	University of Basel	27.11.23

Evaluation of Research Projects and Publications (peer review)

Annette Mollet Journal of Frontiers in Pharmacology. Expert:

- Annette Mollet is chairing the expert committee for the Registration of Radioactive Drugs at Swissmedic and the Swiss Office of Public Health
- Member of working group to update the PharmaTrain syllabus, chairing the Regulatory group
- Organising committee of the Annual Symposium in Pharmaceutical Medicine: Optimising Patient Engagement and Ensuring Access to Treatment, Florhof Zurich, November 29, 2023

Matthias Schwenkglens is a member of the Editorial Board of Pharmacoeconomics. He is a reviewer for a number of additional clinical and health economic journals, recently including BMJ Open, European Journal of Health Economics, Medical Decision Making, Nursing Sciences, Swiss Medical Weekly

PhD Theses Supervised by the ECPM Collaborators in 2023

Helena Aebersold, Health economic aspects of atrial fibrillation: analyses based on the Swiss AF cohort study (working title; PhD thesis at University of Zürich).

Supervised by Matthias Schwenkglenks (primary advisor); graduated 06/2023).

Alexandra Griessbach, Making clinical trials more affordable – trial costs, budget planning, and platform trials (PhD thesis).

Supervised by Matthias Briel (primary advisor), Thomas Szucs (secondary advisor) and Matthias Schwenkglenks (tertiary advisor).

Flurina Meier, Predictors of health care utilization and costs as well as influence of the COVID-19 lockdown on loneliness and social isolation in community-dwelling elderly persons (PhD thesis in cooperation with ZHAW).

Supervised by Nicole Probst (primary advisor) and Matthias Schwenkglenks (secondary advisor).

Niklaus Meier, Cost-effectiveness analyses of medical interventions including gene therapies for haemophilia (PhD thesis in cooperation with Berner Fachhochschule).

Supervised by Matthias Schwenkglenks (primary advisor).

Kimon Papadopoulos, Reaching Conceptual Equivalence on the Concept of Public Trust in Electronic Health Records (EHRs) on a National Level in a Multi-National European Context working title; PhD thesis at University of Zürich.

Supervised by Felix Gille (primary advisor), Viktor von Wyl (responsible faculty member), Matthias Schwenkglenks (further faculty member).

Tabea Frei, Music therapy and chronic pain – A systematic review (Dr Sc Med Student at UFL).

Supervised by Thomas Szucs.

Master Theses: MBA, MMD and MPH

Esther Schaffner, Art 8 dsg Requests for Information in Swiss Hospitals (Master of Public Health Student at University of Zurich).

Supervised by Thomas Szucs.

Katja Meier, Knowledge of Medical Law Among Medical Students (Medical Student at University of Zurich).

Supervised by Thomas Szucs.

Imprint

Published by:

University of Basel
ECPM
Institute of
Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

Design Concept and Layout:
atelier w, Basel


Cover:
© atelier w, Basel

Photography:
Page 3, 6:
© Ursula Sprecher, Basel

Page 15, 25, 28, 31, 35, 37, 41:
© Samuel Bosshardt, Basel

Page 9:
@ Atelier Fontana, Basel

All rights reserved. Copies and re-
production of any kind require the
permission of the editor.



**Educating
Talents**
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

